Molecular characterization and phylogenetic analysis of quinolone resistance-determining regions (QRDRs) of gyrA, gyrB, parC and parE gene loci in viridans group streptococci isolated from adult patients with cystic fibrosis

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 3, 2011, Pages 476-486

  Maeda, Yasunori ^a,b   Murayama, Mayumi ^a,c   Goldsmith, Colin E ^a   Coulter, Wilson A ^d   Mason, Charlene ^d   Millar, B Cherie ^a   Dooley, James S G ^b   Lowery, Colm J ^b   Matsuda, Motoo ^c   Rendall, Jacqueline C ^a   Elborn, J Stuart ^a,e   Moore, John E ^a,b  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

^c AZABU UNIVERSITY   (Japan)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Antibiotic resistance; CF; Ciprofloxacin; Commensal; Pneumococci; Streptococcus; VGS

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; BACTERIAL DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; QUINOLONE DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; QUINOLONE;

ADULT; ALPHA HEMOLYTIC STREPTOCOCCUS; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BROTH DILUTION; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG TRANSPORT; ERADICATION THERAPY; FEMALE; GENE LOCUS; GENE STRUCTURE; GYRA GENE; GYRB GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PARC GENE; PARE GENE; PATHOGENESIS; PHYLOGENY; PSEUDOMONAS AERUGINOSA; QUINOLONE RESISTANCE DETERMINING REGION; SEQUENCE ANALYSIS; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS GORDONII; STREPTOCOCCUS MILLERI; STREPTOCOCCUS MITIS; STREPTOCOCCUS MUTANS; STREPTOCOCCUS ORALIS; STREPTOCOCCUS PARASANGUINIS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS SALIVARIUS; STREPTOCOCCUS SANGUINIS; CHEMISTRY; DNA SEQUENCE; DRUG UTILIZATION; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; STREPTOCOCCUS INFECTION; ANTIBIOTIC THERAPY; CLINICAL ARTICLE; COMMENSAL; DNA STRUCTURE; GENE MUTATION; GENETIC SIMILARITY; MOLECULAR PHYLOGENY; PSEUDOMONAS INFECTION; SPUTUM CULTURE; STREPTOCOCCUS; STREPTOCOCCUS AUSTRALIS; STREPTOCOCCUS CRISTATUS; STREPTOCOCCUS INFANTIS;

ADULT; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; CYSTIC FIBROSIS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; QUINOLONES; SEQUENCE ANALYSIS, DNA; STREPTOCOCCAL INFECTIONS; VIRIDANS STREPTOCOCCI;

EID: 79951533819     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq485     Document Type: Article

References (22)

1. Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros 2008; 7: 450-3.
2. Moore JE, Shaw A, Howard JL et al. Infection control and the significance of sputum and other respiratory secretions from adult patients with cystic fibrosis. Ann Clin Microbiol Antimicrob 2004; 3: 8.
3. Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3 - management. Thorax 2008; 63: 180-4.
4. Cystic Fibrosis Trust. Antibiotic Treatment for Cystic Fibrosis, Report of the UK Cystic Fibrosis Trust Antibiotic Working Group, Third Edition. 2009. http://www.cftrust.org.uk/ (11 November 2010, date last accessed).
5. Sibley CD, Parkins MD, Rabin HR et al. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci USA 2008; 105: 15070-5.
6. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
7. Millar BC, Xu J, Moore JE. Risk assessment models and contamination management: implications for broad-range ribosomal DNA PCR as a diagnostic tool in medical bacteriology. J Clin Microbiol 2002; 40: 1575-80.
8. Balsalobre L, Ferrándiz MJ, Liñares J et al. Viridans group streptococci are donors in horizontal transfer of topoisomerase IV genes to Streptococcus pneumoniae. Antimicrob Agents Chemother 2003; 47: 2072-81.
9. Ip M, Chau SS, Chi F et al. Fluoroquinolone resistance in atypical pneumococci and oral streptococci: evidence of horizontal gene transfer of fluoroquinolone resistance determinants from Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51: 2690-700.
10. Janoir C, Podglajen I, Kitzis MD et al. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis. J Infect Dis 1999; 180: 555-8.
11. Guerin F, Varon E, Hoï AB et al. Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci. Antimicrob Agents Chemother 2000; 44: 2197-200.
12. Pan XS, Ambler J, Mehtar S et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40: 2321-6.
13. Muñoz R, De La Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother 1996; 40: 2252-7.
14. Heaton VJ, Goldsmith CE, Ambler JE et al. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms. Antimicrob Agents Chemother 1999; 43: 2998-3000.
15. Adam HJ, Schurek KN, Nichol KA et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob Agents Chemother 2007; 51: 198-207.
16. Marrer E, Satoh AT, Johnson MM et al. Global transcriptome analysis of the responses of a fluoroquinolone-resistant Streptococcus pneumoniae mutant and its parent to ciprofloxacin. Antimicrob Agents Chemother 2006; 50: 269-78.
17. Marrer E, Schad K, Satoh AT et al. Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of Streptococcus pneumoniae. Antimicrob Agents Chemother 2006; 50: 685-93.
18. Brenwald NP, Gill MJ, Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2032-5.
19. Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 187-9.
20. Li XZ. Quinolone resistance in bacteria: emphasis on plasmid-mediated mechanisms. Int J Antimicrob Agents 2005; 25: 453-63.
21. Humbert O, Prudhomme M, Hakenbeck R et al. Homeologous recombination and mismatch repair during transformation in Streptococcus pneumoniae: saturation of the Hex mismatch repair system. Proc Natl Acad Sci USA 1995; 92: 9052-6.
22. Whatmore AM, Barcus VA, Dowson CG. Genetic diversity of the streptococcal competence (com) genelocus. J Bacteriol 1999;181: 3144-54.